Clinical trial
SCION: SABR and Checkpoint Inhibition of NSCLC
NCT04944173
Study timeline
Study start (actual)2023-08-11Date precision: day
Registry last updated2024-09-03
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non Small Cell Lung Cancerunresolved
Carcinoma, Non-Small-Cell Lungunresolved
Non-small Cell Lung Cancer Stage Iunresolved
Lung Cancerunresolved
Lung Cancer Stage Iunresolved
Lung Adenocarcinoma, Stage Iunresolved
Lung Squamous Cell Carcinoma Stage Iunresolved
Interventions
DurvalumabDRUG · verified · RxNorm: durvalumab
Stereotactic Body RadiotherapyRADIATION
Circulating Tumor DNA assayDIAGNOSTIC_TEST
Sponsors & collaborators
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04944173 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.